D016B9Z
Brachytherapy Spinal Cord to None with Iodine 125 (I-125), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 0 Central and Peripheral Nervous System |
| Operation | 1 Brachytherapy |
| Body Part | 6 Spinal Cord |
| Approach | B Low Dose Rate (LDR) |
| Device | 9 Iodine 125 (I-125) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the central and peripheral nervous system is a radiation treatment in which a radioactive source is placed directly into or next to nervous system tissue, most often within the cavity left after a brain tumor is surgically removed. Rather than aiming beams through the skull from an external machine, this approach delivers radiation from a source positioned at very close range, allowing a concentrated dose to the tissue at highest risk of tumor recurrence while limiting exposure to the rest of the brain.
It is used selectively, often for certain malignant brain tumors where the surgical team places catheters or radioactive seeds at the time of tumor resection, or in a planned procedure shortly afterward. The therapy may involve a temporary source removed after the treatment period or, less commonly, permanently implanted material that decays over time.
Anatomy & Axis Detail
Spinal Cord
Brachytherapy of the spinal cord involves placing a radioactive source within or immediately adjacent to the cord itself, an approach used selectively for recurrent intramedullary tumors or in intraoperative settings following resection, where a boost of localized dose is wanted without irradiating the full length of surrounding vertebral column. The cord's confinement within the bony spinal canal limits surgical access and source geometry, and its low tolerance for radiation injury means the treated segment and prescribed dose must be documented precisely, since retreatment options later in that same region will be constrained by cumulative exposure. This differs meaningfully from brachytherapy targeting vertebral or paraspinal tissue, where the cord may lie near but outside the treatment volume.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Iodine 125 (I-125)
Iodine-125 is a low-energy, low-dose-rate radioisotope most often loaded into small permanent seeds implanted directly into tissue, commonly for early-stage prostate cancer or ocular tumors via plaque brachytherapy. Its longer half-life (about 60 days) gives a slower, more protracted dose delivery than Pd-103 or Cs-131, which is the key distinction among the permanent-seed isotopes.
Coding & Documentation
Coding requires documentation that a radioactive source was physically placed within or adjacent to nervous system tissue, along with whether the source was intended as a temporary placement to be removed later or a permanent implant, since this determines the qualifier. The operative report should identify the specific nervous system structure treated and the isotope or device used to deliver the dose.
A frequent error is coding the catheter or applicator placement itself as the therapy code when the radioactive source has not yet been loaded, since some brachytherapy is delivered in a staged fashion with the source inserted afterward in a separate procedure. Coders should also make sure the resection of the tumor, if performed in the same session, is captured with a separate procedure code rather than folded into the radiation code.
Commonly Confused With
This family is commonly confused with Beam Radiation of the nervous system, since both treat the same body system with therapeutic radiation; the difference is that brachytherapy places the source directly at the treatment site rather than delivering radiation from an external machine. It is also sometimes confused with the surgical placement of a drug-delivery wafer or other implant during tumor resection, which is coded as a device implantation rather than radiation therapy unless the material itself is radioactive.